Earnings lookahead – Lloyds, GlaxoSmithKline, RBS

A look at earnings next week.

Source: Bloomberg

Lloyds Banking Group (Q3 update 25 October)

At just 9.1 times forward earnings versus 13.6 for its sector peers, Lloyds still looks attractive, helped by a steady rise in underlying earnings. One worry is still the further costs for payment protection insurance (PPI) claims, an issue that refuses to go away, while Lloyds’ increased presence in credit cards means the potential for higher bad loans. As ever, it is the dividend that makes Lloyds attractive, especially since the share price has essentially gone nowhere for months.

The shares faltered recently at 68p, but the bounce from 62p has been maintained, as the 50-day simple moving average (SMA) of 65.5p comes into play. Further gains would target 69p, and then 71p. A move below 65p would head towards the September low at 62p. 

GlaxoSmithKline (Q3 earnings 25 October)

GlaxoSmithKline's (GSK's) figures come following mixed numbers from Reckitt Benckiser and Unilever, with GSK’s consumer healthcare division in focus as a result. The new CEO has begun her programme of asset sales, and we look for further updates on this point. The drug division has suffered, thanks to the decline of revenues from Advair; so cost-saving and margin-boosting efforts remain on the agenda. At 13.6 times forward earnings versus a two-year average of 15.3, and a 5.2% yield against a sector average of 2.5%, GSK still has a lot going for it.

The shares have rallied hard from their September lows, but have faltered at the key £15.43 level, the peak from August and previously the support back in April. Above here the £16.50 highs from July come into play. Further downside would see the shares head back to the £14.50 low.

Royal Bank of Scotland (Q3 update 27 October)

Is there any light at the end of the tunnel for Royal Bank of Scotland (RBS)? Perhaps. The return to dividend payments for Lloyds meant RBS, by comparison, looked even worse. The shares have been cheap for a long time, at 11.4 times forward earnings for 2018. A strong operating margin of 36.00% versus the seven-year average of 18.50% helps to boost profitability. If RBS moves towards a dividend payment, then the combination of low valuations plus a payout makes the firm look more attractive. A first-half adjusted operating profit of £3 billion shows that the bank is doing something right.

2017 has been a bumper year for RBS, with the surge from the September lows taking the shares to levels seen since the beginning of 2016. Pullbacks should remain buying opportunities, with 271p and then 260p as potential support. Any drop that holds above 240p remains a higher low, and thus the outlook would remain bullish. 

IGA, may distribute information/research produced by its respective foreign marketing partners within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

This information/research prepared by IGA or IG Group is intended for general circulation. It does not take into account the specific investment objectives, financial situation or particular needs of any particular person. You should take into account your specific investment objectives, financial situation or particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. In addition to the disclaimer above, the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.

See important Research Disclaimer.

Find articles by writer